SOMN PHAR 
By
October 31, 2012
Conference call scheduled today at 4:30 p.m. ET (1:30 p.m. PT); Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, Oct. 31, 2012 (GLOBE NEWSWIRE) -- Somaxon
Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty
pharmaceutical company, today reported its financial results
for the third quarter ended September 30, 2012.
"During the third quarter of 2012, we continued to focus
on our key corporate objectives relating to Silenor
commercialization and intellectual property protection, our
financial position and our strategic alternatives
process," said Richard W. Pascoe, Somaxon's
President and Chief Executive Officer. "Commercially, we
have continued to stabilize Silenor prescription volume
quarter-over-quarter, and we have made solid progress in our
managed care efforts, particularly with respect to the
Medicare Part D market."
"We also settled our Silenor paragraph IV litigation
with three of the four generic filers, we bolstered our
balance sheet through a registered direct offering and we
continue to manage our operating expenses in an effort to
drive towards profitability," continued Pascoe.
"The progress we made in the quarter with respect to
each of these objectives has positioned us to be actively
engaged in our strategic alternatives process with our
advisor, Stifel Nicolaus Weisel, with the objective of fully
leveraging Silenor for the benefit of our stockholders."
